Evaluation of GeneXpert MTB/RIF system performances in the diagnosis of extrapulmonary tuberculosis

BMC Infectious Diseases - 2019
Youness Mechal1, Elmostafa Benaissa1, Nadia El Mrimar1, Yassine Benlahlou1, Fatna Bssaibis2, A. Zegmout3, Mariama Chadli2, Yashpal Singh Malik4, Nadia Touil5, A. Abid3, Adil Maleb6, Mostafa Elouennass2
1Epidemiology and bacterial resistance research team/BIO-INOVA Centre, Faculty of Medicine and Pharmacy (University Mohammed V), Rabat, Morocco
2Department of Bacteriology, Mohammed V Military Teaching Hospital / Faculty of Medicine and Pharmacy (University Mohammed V), Rabat, Morocco
3Pneumology Department, Mohammed V University Hospital / Faculty of Medicine and Pharmacy (University Mohammed V), Rabat, Morocco
4Indian Veterinary Research Institute (IVRI), Bareilly, Uttar Pradesh, India
5Research and Biosafety Laboratory, Mohammed V Military Teaching Hospital / Faculty of Medicine and Pharmacy (University Mohammed V), Rabat, Morocco
6Laboratory of Microbiology, Mohammed VI University Hospital / Faculty of Medicine and Pharmacy (University Mohammed the first), Oujda, Morocco

Tóm tắt

AbstractBackgroundTuberculosis represents a serious public health problem and a significant diagnostic and therapeutic challenge worldwide. Molecular diagnostic techniques are crucial in the World Health Organization’s new tuberculosis control strategy.This study aims to evaluate the performance of GeneXpert MTB/RIF (Cepheid Sunnyvale, CA, United States) in diagnosis of extra-pulmonary tuberculosis then compare it’s performance in detecting Rifampicin resistance to GenoType MTBDRplus (HAIN Life Sciences, Nehren, Germany).MethodsSamples from pulmonary and/or extra-pulmonary origins were analysed in a 21 months retrospective study. Samples were sent to the bacteriology laboratory forMycobacterium tuberculosisdetection using conventional bacteriological and molecular methods (GeneXpert MTB/RIF and MTBDRplus). Sensitivity and specificity were calculated for the stained smear and GeneXpert according to culture (Gold Standard) as well as for GeneXpert MTB/RIF in both negative and positive microscopy tuberculosis cases. Data’s statistical analysis was performed with SPSS13.0 software.ResultsSeven hundred fourteen patients’ samples were analysed; the average age was 47.21 ± 19.98 years with a male predominance (66.4%). Out of 714 samples: 285 were from pulmonary and 429 were from extra-pulmonary origins. The positivity rates for microscopy, GeneXpert MTB/RIF and culture were 12.88, 20.59 and 15.82%, respectively. These rates were 18.9, 23.85 and 20.35% for pulmonary samples and 9.71, 18.41 and 12.82% for extra-pulmonary samples, respectively. The sensitivity and specificity of GeneXpert MTB/RIF were almost the same in both pulmonary and extra-pulmonary samples (78.2 and 90.4%) and (79,3 and 90.3%) respectively.Rifampicin resistance rate found by GeneXpert MTB/RIF was 0.84%. Comparison of Rifampicin resistance obtained by GeneXpert MTB/RIF and Genotype MTBDRplus, showed 100% agreement between the two techniques for studied samples.ConclusionsThis confirms GeneXpert MTB/RIF advantage for tuberculosis diagnosis, particularly extra-pulmonary tuberculosis with negatively stained smear. The performance of GeneXpert and Genotype MTBDRplus are similar in detection of Rifampicin resistance. However, variability of detection performance according to tuberculosis endemicity deserves more attention in the choice of screening techniques of Rifampicin resistance, hence the interest of conducting comparative studies of detection performance under low and medium endemicity on large samples of tuberculosis populations.

Từ khóa


Tài liệu tham khảo

Organisation Mondiale de la Santé Rapport sur la lutte contre la tuberculose dans le monde 2017. Organisation Mondiale de la Santé; 2017. https://www.who.int/tb/publications/global_report/gtbr2017_executive_summary_fr.pdf?ua=1. Accessed 19 Jan 2019.

World Health Organization. Global tuberculosis Report 2018. S.l.: World Health Organization; 2018.

World Health Organization. Tuberculosis profile - Morocco. 2017. www.who.int/tb/data. Accessed 17 Jan 2019.

Purohit M, Mustafa T. Laboratory diagnosis of extra-pulmonary tuberculosis (EPTB) in resource-constrained setting: state of the art, challenges and the need. J Clin Diagn Res. 2015;9:EE01–6.

Lee JY. Diagnosis and treatment of Extrapulmonary tuberculosis. Tuberc Respir Dis. 2015;78:47.

Parrish NM, Carroll KC. Role of the clinical Mycobacteriology Laboratory in Diagnosis and Management of tuberculosis in low-prevalence settings. J Clin Microbiol. 2011;49:772–6.

Loïez-Durocher C, Vachée A, Lemaitre N. La résistance de Mycobacterium tuberculosis aux antituberculeux : méthodes diagnostiques. Ann Biol Clin. 2000;58(3):291–7.

Mondiale dela Santé O. Définitions et cadre de notification pour la tuberculose–Révision 2013; 2014.

Guillet-Caruba C, Martinez V, Doucet-Populaire F. Les nouveaux outils de diagnostic microbiologique de la tuberculose maladie. Rev Med Interne. 2014;35:794–800.

Iram S, Zeenat A, Hussain S, Wasim Yusuf N, Aslam M. Rapid diagnosis of tuberculosis using Xpert MTB/RIF assay - report from a developing country. Pak J Med Sci. 2015;31:105–10.

Matabane MMZ, Ismail F, Strydom KA, Onwuegbuna O, Omar SV, Ismail N. Performance evaluation of three commercial molecular assays for the detection of mycobacterium tuberculosis from clinical specimens in a high TB-HIV-burden setting. BMC Infect Dis. 2015;15:508.

Rahman A, Sahrin M, Afrin S, Earley K, Ahmed S, Rahman SMM, et al. Comparison of Xpert MTB/RIF assay and GenoType MTBDRplus DNA probes for detection of mutations associated with rifampicin resistance in mycobacterium tuberculosis. PLoS One. 2016;11. https://doi.org/10.1371/journal.pone.0152694.

Rufai SB, Kumar P, Singh A, Prajapati S, Balooni V, Singh S. Comparison of Xpert MTB/RIF with line probe assay for detection of rifampin-Monoresistant mycobacterium tuberculosis. J Clin Microbiol. 2014;52:1846–52.

Rüsch-Gerdes S, Pfyffer GE, Casal M, Chadwick M, Siddiqi S. Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J Clin Microbiol. 2006;44:688–92.

HAIN LifeScience. GenoType MTBDRplus VER 2.0 instructions for use. Nehren: Document IFU-304A-06; 2015.

Li S, Liu B, Peng M, Chen M, Yin W, Tang H, et al. Diagnostic accuracy of Xpert MTB/RIF for tuberculosis detection in different regions with different endemic burden: a systematic review and meta-analysis. PLoS One. 2017;12. https://doi.org/10.1371/journal.pone.0180725.

Opota O, Zakham F, Mazza-Stalder J, Nicod L, Greub G, Jaton K. Added Value of Xpert MTB/RIF Ultra for Diagnosis of Pulmonary Tuberculosis in a Low-Prevalence Setting. Journal of Clinical Microbiology. 2019;57:e01717-18. https://doi.org/10.1128/JCM.01717-18

Ozkutuk N, Surucüoglu S. Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary tuberculosis in an intermediate-prevalence setting. Mikrobiyol Bul. 2014;48:223–32.

Chiang T-Y, Fan S-Y, Jou R. Performance of an Xpert-based diagnostic algorithm for the rapid detection of drug-resistant tuberculosis among high-risk populations in a low-incidence setting. PLoS One. 2018;13:e0200755.

Rice JP, Seifert M, Moser KS, Rodwell TC. Performance of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis and rifampin resistance in a low-incidence, high-resource setting. PLoS One. 2017;12:e0186139.

Package Insert. CGXMTB/RIF-50.301–0976. 2012.

Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2014. https://doi.org/10.1002/14651858.CD009593.pub3.

Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010;363:1005–15.

Tang T, Liu F, Lu X, Huang Q. Evaluation of GeneXpert MTB/RIF for detecting mycobacterium tuberculosis in a hospital in China. J Int Med Res. 2017;45:816–22.

el Baghdadi J, Lazraq R, Ibrahimy S, Bouayad Z, Guinet R, Benslimane A. Survey of primary drug resistance of mycobacterium tuberculosis in Casablanca. Morocco Int J Tuberc Lung Dis. 1997;1:309–13.

Karimi H, En-Nanai L, Oudghiri A, Chaoui I, Laglaoui A, Bourkadi JE, et al. Performance of GenoType® MTBDRplus assay in the diagnosis of drug-resistant tuberculosis in Tangier, Morocco. J Glob Antimicrob Resist. 2018;12:63–7.

Chakravorty S, Simmons AM, Rowneki M, Parmar H, Cao Y, Ryan J, et al. The New Xpert MTB/RIF Ultra: Improving Detection of Mycobacterium tuberculosis and Resistance to Rifampin in an Assay Suitable for Point-of-Care Testing. mBio. 2017;8. doi:https://doi.org/10.1128/mBio.00812-17.

Köser CU, Feuerriegel S, Summers DK, Archer JAC, Niemann S. Importance of the genetic diversity within the mycobacterium tuberculosis complex for the development of novel antibiotics and diagnostic tests of drug resistance. Antimicrob Agents Chemother. 2012;56:6080–7.

Blakemore R, Story E, Helb D, Kop J, Banada P, Owens MR, et al. Evaluation of the analytical performance of the Xpert MTB/RIF assay. J Clin Microbiol. 2010;48:2495–501.

Zetola NM, Shin SS, Tumedi KA, Moeti K, Ncube R, Nicol M, et al. Mixed mycobacterium tuberculosis complex infections and false-negative results for rifampin resistance by GeneXpert MTB/RIF are associated with poor clinical outcomes. J Clin Microbiol. 2014;52:2422–9.

Bennani K, Elhassani S, Ottmani S, Pirou Y, Sghiar M, Youbi M, et al. Enquête de prévalence nationale de la résistance aux médicaments antituberculeux au Maroc. Bulletin d'Epidémiologie et de Santé Publique; Volume 50; N°75. p. 19.

World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system for the diagnosis of pulmonary and extrapulmonary TB in adults and children. Geneva: WHO; 2013. https://apps.who.int/iris/handle/10665/112472.

Organization WH, et al. Resolution WHA67. 1. Global strategy and targets for tuberculosis prevention, care and control after 2015. 2016.

Thông tin
Thông tin xuất bản

BMC Infectious Diseases

Thông tin tác giả